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Abstract: A high fat diet (HFD) intake is crucial for the development and progression of metabolic
syndrome (MtS). Increasing evidence links gut dysbiosis with the metabolic and vascular alterations
associated with MtS. Here we studied the use of a combination of various probiotic strains together
with a prebiotic (synbiotic) in a commercially available Prodefen® Plus. MtS was induced by HFD (45%)
in male Wistar rats. Half of the MtS animals received Prodefen® Plus for 4 weeks. At 12 weeks, we
observed an increase in body weight, together with the presence of insulin resistance, liver steatosis,
hypertriglyceridemia and hypertension in MtS rats. Prodefen® Plus supplementation did not affect
the body weight gain but ameliorated all the MtS-related symptoms. Moreover, the hypertension
induced by HFD is caused by a diminished both nitric oxide (NO) functional role and release probably
due to a diminished neuronal nitric oxide synthase (nNOS) activation by protein kinase A (PKA)
pathway. Prodefen® Plus supplementation for 4 weeks recovered the NO function and release and the
systolic blood pressure was returned to normotensive values as a result. Overall, supplementation
with Prodefen® Plus could be considered an interesting non-pharmacological approach in MtS.
Keywords: metabolic syndrome; synbiotic; hypertension; superior mesenteric artery; perivascular
nitrergic innervation; nitric oxide; neuronal nitric oxide synthase; protein kinase a
1. Introduction
Obesity affected two billion people worldwide in 2015 with annual costs reaching two trillion
USD [1]. The global prevalence has increased dramatically in the last four decades, reaching 10.8%
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in adult men and 14.9% in adult women [2]. Chronic consumption of a high-fat diet (HFD) induces
overweight and is the main trigger for the development of metabolic syndrome (MtS) characterized
by dyslipidemia, hypertension and impaired glucose homeostasis [3,4]. MtS is associated with high
mortality and morbidity due to an increase in the prevalence of cardiovascular diseases, diabetes,
chronic kidney diseases, cancer and musculoskeletal diseases [2].
The accumulation of adipose tissue promotes a pro-inflammatory and pro-oxidative
microenvironment, leading to a chronic low-grade inflammation state [5]. Moreover, the secretion of
adipokines from the adipose tissue alters the function of multiple vasoactive factors, increases peripheral
vascular resistance and leads to hypertension. Evidence indicates that the blood flow and tissue
perfusion required for cardiovascular system homeostasis is affected by nitric oxide (NO) synthesis [6,7].
Other factor implicated in the regulation of vascular resistance is perivascular innervation, specifically
in certain vessels such as the mesenteric vascular bed, where blood flow is approximately 20–30%
of the total cardiac output [8]. Previously we have reported that the neural control of mesenteric
vasomotor tone is altered in rats fed on HFD for a short term, partly due to a decrease in neuronal NO
release from perivascular nitrergic innervation [9,10].
Increasing evidence links the development of MtS and chronic low-grade inflammation to
dysbiosis, an imbalance in the intestinal flora [11–13]. Some studies demonstrated that dysbiosis
promotes the development of low-grade inflammation and consequently MtS, and others that dysbiosis
is the result of low-grade inflammation during obesity and MtS. Either way, the modulation of dysbiosis
by dietary strategies based on alterations of gut microbiome improves the health outcome of MtS [14].
The supplementation of probiotics, live bacterial strains, have been shown to modulate the alteration
of gut microbiome [15] and to improve MtS symptoms, such as insulin resistance, lipid profile and
high blood pressure in animal models [16,17].
It is considered that multistrain and/or multi-species probiotics have been shown in animal
models to be more effective than monostrain probiotics [18]. Additionally, the use of prebiotics,
non-digestible oligosaccharides that stimulates the growth of desired bacteria, together with a probiotic
is more effective than probiotics alone by improving survival and implantation of live microbes
in the gastrointestinal tract [19]. The commercial synbiotic formulation Prodefen® Plus combines
various probiotic strains (Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus
bulgaricus, Streptococcus thermophilus, Bifidobacterium breve and Bifidobacterium infantis) together with a
prebiotic, fructooligosaccharides. Both Prodefen® Plus, and a similar synbiotic commercial formula
Prodefen® exert a beneficial effect in antibiotic-associated diarrhoea and acute gastroenteritis in
children, respectively [20,21]. Regarding MtS, Prodefen® has shown an antihypertensive effect in
spontaneously hypertensive rats [22]. Nevertheless, the possible beneficial effect of Prodefen® Plus in
MtS remains unknown.
Given the above, we hypothesized that a supplementation with the commercially available
synbiotic formula Prodefen® Plus might improve the cardiometabolic alterations related to MtS, leading
to a reduction in the administration of any pharmacological treatment. Hence, in the present study we
aim to assess the effect of Prodefen® Plus in rats fed on HFD that develop MtS, with a special focus on
the understanding of the vascular mechanisms implicated in the development of hypertension.
2. Materials and Methods
2.1. Animals and Diet
All experimental procedures were approved by the Ethical Committee of the Universidad
Autónoma de Madrid, and the Comunidad de Madrid (PROEX 322/16), are in compliance with NIH
guidelines and follow the European Parliament Directive 2010/63/EU guidelines. Twenty-four male
Wistar rats (initial weight 209.5 ± 3.1 g) were purchased from Harlan Ibérica SL, Barcelona, Spain
and housed in the Animal Facility of the Universidad Autónoma de Madrid (Registration number
EX-021U). Rats were held in groups of 2 in appropriate cages in controlled environmental conditions
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(20–24 ◦C, 55% relative humidity and 12 h light-dark cycle). All rats had access to drinking water and
specific rat chow ad libitum.
Animals were randomly divided into three groups: (I) Rats fed a commercial standard diet (4.0%
fat; 2.9 Kcal/g; Tekland global rodent diet 2014, ENVIGO, Huntingdon, UK) for 12 weeks as a control
group (CT; n = 8); (II) rats with metabolic syndrome (MtS, n = 8), fed a HFD (45% fat; 4.6 Kcal/g; 58V8,
TestDiet, Columbia, USA) for 12 weeks; and (III) rats with MtS, fed a HFD (45% fat, 4.6 Kcal/g) for
12 weeks, supplemented with the multistrain synbiotic Prodefen® Plus (adjusted doses to 107 colony
forming units (c.f.u.)/day) for the last 4 weeks (MtS-SYNB, n = 8).
Prodefen® Plus (formulation which combines 990 mg of fructooligosaccharides with various
probiotic strains −1010 c.f.u. Lactobacillus rhamnosus LGG and 109 c.f.u. of a mixture of: Lactobacillus
casei, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium infantis
and Lactobacillus bulgaricus), was generously provided by Italfarmaco S.A. This synbiotic formula was
administered to the rats dissolved in drinking water, once the obesity had been stablished [9,10].
The dose (107 c.f.u./day) and administration time (4 weeks) of Prodefen® Plus was chosen based on
preliminary pilot studies, choosing the lowest dose/time in which we found a systemic effect. The body
weight was measured every two weeks. During the last 4 weeks, the water intake was measured every
two days to assure the intake of appropriate dose of the synbiotic. The summary of the experimental
procedure is represented in Figure 1.
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2.1.1. Glucose Tolerance Test 
The oral glucose tolerance test (GTT) was performed at 0, 8 and 12 weeks according to a standard 
protocol [23,24]. After an overnight fasting, a single oral dose (2 g/kg of body weight) of glucose was 
delivered. Blood glucose was then measured from the tail vein just before, and at 15, 30, 60, 90 and 
120 min after glucose intake, using test strips and reader (FreeStyle Optium®, Abbot Laboratories 
S.A., Madrid, Spain) (Figure 1). 
2.1.2. Systolic Blood Pressure 
The systolic blood pressure was measured at 0, 8 and 12 weeks in awake rats by a tail-cuff 
method, using a caudal artery plethysmograph (NIPREM 645, Cibertec S.A., Madrid, Spain) as 
published previously [9]. (Figure 1) 
2.2. Animal Euthanasia, Sample Collection and Sample Analysis 
After an overnight fasting, rats were anesthetized (100 mg/kg ketamine hydrochloride and 12 
mg/kg Xylazine; i.m.) and euthanized by exsanguination by the infrahepatic inferior cava vein 
puncture. Visceral and epididymal white adipose pads were collected for posterior dissection. Left 
tibia length was measured as a parameter to evaluate body weight. 
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Figure 1. Diagrammatic representation of the 12-weeks experimental procedure. Abbreviations: body
weight (BW), glucose tol ranc tes (GTT), systolic blood ressure (SBP).
2.1.1. Glucose Tolerance Test
The oral glucose tolerance test (GTT) was performed at 0, 8 and 12 weeks according to a standard
protocol [23,24]. After an overnight fasting, a single oral dose (2 g/kg of body weight) of glucose was
delivered. Blood glucose was then measured from the tail vein just before, and at 15, 30, 60, 90 and
120 min after glucose intake, using test strips and reader (FreeStyle Optium®, Abbot Laboratories S.A.,
Madrid, Spain) (Figure 1).
2.1.2. Systolic Blood Pressure
The systolic blood pressure was measured at 0, 8 and 12 weeks in awake rats by a tail-cuff method,
using a caudal artery plethysmograph (NIPREM 645, Cibertec S.A., Madrid, Spain) as published
previously [9]. (Figure 1)
2.2. Animal Euthanasia, Sample Collection and Sample Analysis
After an overnight fasting, rats were anesthetized (100 mg/kg ketamine hydrochloride and
12 mg/kg Xylazine; i.m.) and euthanized by exsanguination by the infrahepatic inferior cava vein
puncture. Visceral and epididymal white adipose pads were collected for posterior dissection. Left
tibia length was measured as a parameter to evaluate body weight.
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2.2.1. Liver Histology
Liver was extracted, rinsed in a saline solution and weighed. The left lateral liver lobe was
cryoprotected (30% w/v sucrose in phosphate saline buffer) and frozen at −70 ◦C until use. Liver
samples were embedded in optimum cutting temperature compound (OCT Tissue Tek, Sigma-Aldrich,
Madrid, Spain), 5 µm cryostat sections were stained with lipid dye Sudan III and random images were
taken at 20×magnification. Quantification was performed using Image-Pro Plus 7 software (Media
Cybernetics, MD, USA).
2.2.2. Serum Biochemical Parameters
Blood samples were kept at room temperature for 2 h and were centrifuged afterwards (2000× g
15 min, 4 ◦C). The serum was then collected and kept at −70 ◦C until use. Serum concentration of total
cholesterol (TC), triglycerides (TG) and high density lipoproteins (HDL) were measured by biochemical
analyser RAL LC5 (Barcelona, Spain). Low density lipoprotein (LDL) levels were indirectly calculated
using the Friedewald formula: LDL = TC-((TG/5) + HDL) as published previously [25].
2.2.3. Vascular Reactivity
The superior mesenteric artery was carefully dissected, cleaned of connective tissue and maintained
at 4 ◦C in Krebs-Henseleit solution (in mmol/L: 115 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4.7H2O,
2.5 CaCl2, 1.2 KH2PO4, 11.1 glucose, and 0.01 Na2EDTA) bubbled with a 95% O2 5% CO2 mixture until
use. The segments were endothelium-denuded by gently rubbing the luminal surface of the segments
with a thin wooden stick to eliminate the main source of vasoactive substances. Some segments were
quickly frozen in liquid nitrogen and maintained at −70 ◦C.
Vascular reactivity experiments were performed in endothelium denuded segments of 2 mm
length according to previously published method [26]. Briefly, two parallel stainless-steel pins were
introduced through the lumen of the vascular segment: one was fixed to the bath wall and the other
connected to a force transducer (Grass FTO3C; Quincy, MA, USA) that was connected to a model 7D
Grass polygraph. For electric field stimulation (EFS) experiments, segments were mounted between
two platinum electrodes 0.5 cm apart and connected to a stimulator (Grass, model S44) modified to
supply the appropriate current strength. Segments were suspended in an organ bath containing 5 mL
of KHS at 37 ◦C continuously bubbled with a 95% O2 5% CO2 mixture (pH 7.4). The segments were
subjected to a tension of 4.9 mN, which was readjusted every 15 min during a 90 min equilibration
period before drug administration. After this, the vessels were exposed to 75 mmol/L KCl to confirm
their functional integrity. The absence of vascular endothelium after the washout period was tested by
the inability of 10 µmol/L acetylcholine (ACh) to relax segments precontracted with noradrenaline.
Endothelium removal did not alter the contractions elicited by KCl [10,23].
Frequency-response curves to EFS (1, 2, 4, 8 and 16 Hz) were performed. The parameters used
for EFS were 200 mA, 0.3 ms, 1–16 Hz, for 30 s with an interval of 1 min between each stimulus, the
time required to recover the basal tone. A washout period of at least 1 h was necessary to avoid
desensitisation between consecutive curves. Two successive frequency-response curves separated by
1 h intervals produced similar contractile responses [26].
To analyse the participation of NO in the EFS-induced response in our experimental procedure,
0.1 mmol/L Nω-nitro-L-arginine methyl ester (L-NAME), a non-specific inhibitor of nitric oxide
synthase, was added to the bath 30 min before performing the second frequency–response curve.
The vasodilator response to the NO donor, diethylamine NONOate, (DEA-NO, 0.1 nmol/L–0.1 mmol/L
was determined in noradrenaline-precontracted segments from all experimental groups.
2.2.4. Nitric Oxide Release
Nitric oxide (NO) release experiments were performed in endothelium-denuded mesenteric
segments using the fluorescence probe 4,5-diaminofluorescein (DAF-2) as previously described [9,10,27].
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Briefly, segments from all the experimental groups were subjected to an equilibration period of 60 min
in HEPES buffer (in mmol/L: NaCl 119; HEPES 20; CaCl2 1.2; KCl 4.6; MgSO4 1; KH2PO4 0.4; NaHCO3
5; glucose 5.5; Na2HPO4 0.15; pH 7.4) at 37 ◦C. Afterwards, arteries were transferred to a HEPES-filled
400 µL chamber and incubated with 2 µmol/L DAF-2 for 30 min. Then the medium was collected to
measure basal NO release. Once the organ bath was refilled, cumulative EFS pulses of 30 s (1, 2, 4, 8
and 16 Hz) were applied at 1 min intervals. The fluorescence of the medium was measured at room
temperature using a spectrofluorometer (Jenway 6280 Fluorimeter) with excitation wavelength set
at 492 nm and emission wavelength at 515 nm. Some segments were incubated with 1 µmol/L H89
(a PKA (protein kinase A) inhibitor), 0.1 µmol/L calfostin C (a PKC (protein kinase C) inhibitor), or
10 µmol/L LY 294002 (a phosphatidylinositol 3-kinase -PI3K- inhibitor). The EFS-induced NO release
was calculated by subtracting basal NO release from that evoked by EFS. Furthermore, blank samples
were collected in the same way from segment-free medium in order to subtract background emission.
The amount of NO released was expressed as arbitrary fluorescence units (A.F.U.)/mg tissue.
2.2.5. PKA and PKC Activity Assays
PKA and PKC activities were determined using a PKA and PKC kinase activity assay kit (Abcam,
Cambridge, UK), respectively following the manufacturers’ protocols. Briefly, frozen arteries from all
experimental groups were homogenised in a lysis buffer (0.01 mmol/L Tris-HCl, 1 mmol/L sodium
vanadate, 1% SDS, pH 7.4), and centrifuged at 12,000× g for 10 min at 4 ◦C. The supernatant was then
collected and used for the assay. Protein content was measured using a DC protein assay kit (BioRad,
Madrid, Spain). Results were expressed as optical density (O.D.) units/µg protein.
2.2.6. Western Blot
Western blot analysis was performed as previously described [8,9]. Briefly, arteries were
homogenized, and 30 µg protein was loaded in each lane. A mouse monoclonal antibody against
neuronal nitric oxide synthase (nNOS, 1:2000, BD Biosciences), a rabbit polyclonal anti-pan-AKT
antibody (1:1000, Abcam), or a rabbit polyclonal anti-pan-AKT (phospho T308, 1:500, Abcam) were
used. The development and quantification of the images were performed using Quantity One software
(Windows v4.6.6, Bio-Rad, Madrid, Spain). The same membrane was used to correct protein expression
in each sample, by means of a monoclonal anti-β-actin−peroxidase antibody (1:50,000; Sigma-Aldrich,
Madrid, Spain).
2.2.7. Detection of Superoxide Anions
Superoxide anion levels were measured using lucigenin chemiluminescence, as previously
described [10,27]. Briefly, endothelium-denuded segments from all experimental groups were
equilibrated for 30 min in HEPES buffer at 37 ◦C, transferred to test tubes that contained 1 mL
HEPES buffer (pH 7.4) with lucigenin (5 µmol/L) and then kept at 37 ◦C. The luminometer
(Optocom I, GEM Biomedical Inc., Hamden, CT, USA) was set to report arbitrary units of
emitted light; repeated measurements were collected (10 s intervals for 5 min) and averaged.
4,5-Dihydroxy-1,3-benzene-disulphonic acid “Tiron” (10 mmol/L), a cell-permeant, non-enzymatic
superoxide anion scavenger, was added to quench the superoxide anion-dependent chemiluminescence.
Blank samples (HEPES without arterial segment) were collected in the same way from culture medium
without mesenteric segments to subtract background emission.
2.3. Drugs Used
L-Noradrenaline hydrochloride, ACh chloride, diethylamine NONOate diethylammonium salt,
Nω-nitro-L-arginine methyl ester (L-NAME) hydrochloride, lucigenin, tiron, DAF-2, calfostin C, H89,
and LY294002 were used. All drugs were purchased from Sigma-Aldrich (Spain) except for LY294002
and H89, which were obtained from Tocris (Spain). Stock solutions (10 mmol/L) of drugs were made
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in distilled water, except for NA, which was dissolved in a NaCl (0.9%)–ascorbic acid (0.01% w/v)
solution, or DAF, H89 and calfostin C and LY294002, which were dissolved in dimethyl sulfoxide.
2.4. Data Analysis
Graph representation and statistical analysis were performed using GraphPad Prism 6.0 software
(CA, USA). The adipose tissue pads and liver weight were normalised using tibia length. The responses
induced by EFS were expressed as a % of the initial contraction elicited by 75 mmol/L KCl. To compare
the effect of preincubation with L-NAME in EFS-induced contraction experiments, differences between
areas under the curve (dAUC) were analysed. The relaxation induced by DEA-NO was expressed
as a % of the initial contraction elicited by NA. Results were expressed as mean ± S.E.M. The body
weight evolution, the glucose tolerance test and the vasomotor responses to DEA-NO or EFS were
compared by means of an unpaired two-way analysis of variance (ANOVA). When comparing the
effect of L-NAME on the EFS-induced contraction, a paired two-way ANOVA was used. For the body
weight gain, food and water intake, lipid profile, blood pressure, KCl, dAUC, NO, superoxide anion,
PKA activity, PKC activity and Western blot densitometry analyses, a Shapiro-Wilk test was applied to
confirm the normality of the population data, followed by a one-way ANOVA with a Newman–Keuls
post-hoc test. p < 0.05 was considered significant.
3. Results
3.1. The Effect of HFD and Synbiotic Supplementation on the Body Weight Gain and Lipid Profile
In the present study we induced obesity in Wistar rats by the administration of a HFD (45% fat).
The obesity was established after 8 weeks. At week eight, eight rats out of 16 fed on a HFD were
administered a commercial synbiotic supplement Prodefen® Plus. After 12 weeks, the body weight
increase was significantly higher in MtS rats compared to CT. The supplementation of Prodefen® Plus
did not affect the body weight in MtS rats (MtS-SYNB) (Figure 2).
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Figure 2. Body weight evolution in CT (control group), MtS (metabolic syndrome) and MtS-SYNB
(MtS rats supplemented with Prodefen®Plus) groups over 12 weeks. Body weight is expressed as
mean ± S.E.M. Statistical analysis: Unpaired two-way ANOVA. * p < 0.05 CT vs. MtS; + p < 0.05 CT vs.
MtS-SYNB. n = eight animals per group.
The body weight increase in MtS and MtS-SYNB group was accompanied by an increase in
epididymal and visceral adipose pads. The food intake in MtS and MtS-SYNB group was lower and
conversely the calories intake was higher. Water intake was comparable among groups (Table 1).
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Table 1. Body weight gain, food and water intake and lipid profile.
Parameters CT MtS MtS-SYNB
Body weight increase 1 (%) 87.8 ± 2.1 111.3 ± 7.1 * 106.1 ± 9.1 +
Epididymal adipose pad 2 (g/cm) 1.66 ± 0.08 3.30 ± 0.34 * 3.44 ± 0.33 +
Visceral adipose pad 2 (g/cm) 1.39 ± 0.06 3.05 ± 0.35 * 3.54 ± 0.30 +
Liver weight 2 (g/cm) 1.91 ± 0.07 2.01 ± 0.09 1.86 ± 0.09
Food intake 3 (g/day) 20.96 ± 0.47 16.48 ± 0.47 * 16.67 ± 0.86 +
Calorie intake 3 (Kcal/day) 60.75 ± 1.34 75.80 ± 2.14 * 76.69 ± 3.93 +
Water intake 3 (mL/day) 36.59 ± 2.08 35.91 ± 1.02 38.16 ± 0.76
TC 4 (mg/dL) 88.88 ± 5.07 81.8 ± 5.37 90.38 ± 5.93
TG 4 (mg/dL) 112.20 ± 55.80 156.00 ± 16.37 * 115.40 ± 6.89 #
HDL 4 (mg/dL) 37.29 ± 2.32 30.37 ± 2.19 35.41 ± 2.57
LDL 4 (mg/dL) 20.61 ± 2.47 25.31 ± 3.53 31.89 ± 3.08
Notes: Data are expressed as mean ± S.E.M. Statistical analysis: One-way ANOVA followed by a Newman–Keuls
post-hoc test. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB; + p < 0.05 CT vs. MtS-SYNB. n = 8 animals per
group. 1 Body weight increase is expressed as % of the initial body weight. 2 Respective weights were normalized
to tibia length (in cm; CT: 5.25 ± 0.03; MtS: 5.26 ± 0.09; MtS-SYNB: 5.19 ± 0.09). 3 Food and water intake were
measured every two days in the last 4 weeks of the experimental procedure coinciding with the administration of
the synbiotic. 4 Serum total cholesterol (TC), triglycerides /TG), high density lipoproteins (HDL) and low density
lipoproteins (LDL) were analysed at the end of the experimental period of 12 weeks. CT (control group), MtS
(metabolic syndrome), MtS rats supplemented with Prodefen®Plus (MtS-SYNB).
Total cholesterol, LDL and HLD levels did not differ between groups, while the levels of plasma
TG were significantly increased in the MtS group as compared to CT group and were returned to control
levels in MtS-SYNB group (Table 1). Given the fact that increased TG levels leads to a development of
liver steatosis, we next analysed the presence of lipids in liver sections by Sudan III lipid dye. Even
though liver weight was comparable among groups, the HFD led to a development of steatosis as
demonstrated by the presence of lipid vacuoles throughout the hepatic left lateral lobe. Interestingly,
supplementation of Prodefen® Plus decreased the level of steatosis, even though not to the control state
(Figure 3).Nutrients 2020, 12, x FOR PEER REVIEW 8 of 19 
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3.2. The Effect of Synbiotic Supplementation on MtS Induced Alterations
MtS is related to several metabolic alterations, therefore next we analysed the effect of HFD and
synbiotic supplementation on glucose homeostasis. Although basal glycemia was comparable among
groups, insulin resistance was developed already at week eight of HFD and was maintained until week
12. The insulin resistance was ameliorated by Prodefen® Plus supplementation, even though not to the
control state (Figure 4).
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Figure 4. Evolution of insulin resistance measured by glucose tolerance test in CT, MtS and MtS-SYNB
rats at the beginning of procedure (a), after 8 weeks of diet intervention (b) and after 12 weeks once the
synbiotic supplementation terminated (c). Results are expressed as mg glucose/dL (mean ± S.E.M).
Statistical analysis: Unpaired two-way ANOVA. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB;
+ p < 0.05 CT vs. MtS-SYNB.
Hypertension is also related to MtS, therefore next we measured the systolic blood pressure using
tail cuff method. At week 0 all the animals showed a normotensive phenotype. At week eight, animals
fed on a HFD showed an increased systolic blood pressure reaching levels considered as hypertension.
The supplementation of Prodefen® Plus for 4 weeks normalized the systolic blood pressure reaching
levels comparable to the control group (Table 2).
Table 2. Systolic blood pressure.
CT MtS MtS-SYNB
Week 0 1 118.5 ± 1.8 110.9 ± 3.0 * 110.1 ± 2.7 +
Week 8 2 119.5 ± 2.4 141.1 ± 1.6 * 137.4 ± 1.0 +
Week 12 3 120.3 ± 3.7 145.3 ± 2.1 * 120.6 ± 1.6 #
Notes: Results are expressed as mmHg (mean ± S.E.M). Statistical analysis: One-way ANOVA followed by a
Newman–Keuls post-hoc test. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB; + p < 0.05 CT vs. MtS-SYNB.
n = eight animals per group.1 Beginning of procedure. 2 Eight weeks of dietary intervention. 3 Twelve weeks of
dietary intervention (4 weeks of synbiotic supplementation in MtS + SYNB group).
3.3. Mechanism of HFD-Induced Hypertension
3.3.1. Nitric Oxide Release
The alterations in blood pressure are partially linked to modifications in peripheral vascular
resistance. Among the multiple vasoactive factors which regulate vascular tone in superior mesenteric
artery, NO has a relevant role, acting as a potent vasodilator. Given the great relevance of nitrergic
innervation in the regulation of mesenteric resistance, we analysed the release of neuronal NO release
in segments from all experimental groups. The application of an EFS pattern induced NO release in
mesenteric segments without endothelium from all groups. As expected, NO release was significantly
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decreased in MtS group as compared to CT group. Interestingly, the supplementation with Prodefen®
Plus for 4 weeks recovered the NO release levels comparable to the control group (Table 3).
Table 3. Nitric oxide and superoxide anion release in endothelium-denuded mesenteric rings.
CT MtS MtS SYNB
NO release (A.F.U./mg tissue) 1 2518 ± 147 1065 ± 10 * 2498 ± 279 #
Superoxide anion
release(C.U./min/mg tissue) 2 55.26 ± 3.01 55.78 ± 8.13 55.74 ± 6.54
Notes: 1 Results are expressed as arbitrary fluorescence units (A.F.U.)/mg tissue. Mean ± S.E.M. Statistical analysis:
One-way ANOVA followed by a Newman–Keuls post-hoc test. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB.
n = five to eight animals per group.2 Results are expressed as chemiluminescence units (C.U.)/minute/mg tissue.
Mean ± S.E.M. n = five to eight animals per group.
3.3.2. Functional Role for Neuronal Nitric Oxide: Vascular Function
Alteration in blood pressure is linked to modifications in smooth muscle sensitivity to nitric oxide
(NO). However, in our model we did not find any differences in the vasodilator response to NO donor
DEA-NO among groups (Figure 5a).Nutrients 2020, 12, x FOR PEER REVIEW 10 of 19 
 
 
Figure 5. (a) Vasodilator response to DEA-NO in mesenteric segments from CT, MtS and MtS-SYNB 
rats. Results are expressed as % of relaxation elicited by NA (in mN: CT: 11.81 ± 1.1; MtS: 12.36 ± 1.03; 
MtS-SYNB: 14.41 ± 1.28). Mean ± S.E.M. (b) Vasoconstrictor response to EFS in mesenteric segments 
from CT, MtS and MtS-SYNB rats. Results are expressed as a % of previous contraction elicited by 
KCI (in mN: CT: 13.03 ± 0.74; MtS: 11.55 ± 0.51; MtS-SYNB: 12.45 ± 0.72). Mean ± S.E.M. Statistical 
analysis: Unpaired two-way ANOVA. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB. 
Next, we aimed to determine whether the observed alteration in NO release have a relevant 
functional role. We applied EFS to induce a frequency-dependent contractile response in 
endothelium-denuded mesenteric segments. An enhanced vasoconstriction response was observed 
in MtS group, and the supplementation with Prodefen® Plus for 4 weeks diminished this 
vasoconstriction response (Figure 5b). We next inhibited the NO synthesis with an unspecific NO 
synthase (NOS) inhibitor L-NAME (0.1 mmol/L) and observed a potentiation in the vasoconstriction 
response in CT and MtS-SYNB groups, while it exerted no effect in arteries from animals from MtS 
group (Figure 6a–d). 
Figure 5. (a) Vasodilator response to DEA-NO in mesenteric segments from CT, MtS and MtS-SYNB
rats. Results are expressed as % of relaxation elicited by NA (in mN: CT: 11.81 ± 1.1; MtS: 12.36 ± 1.03;
MtS-SYNB: 14.41 ± 1.28). Mean ± S.E.M. (b) Vasoconstrictor response to EFS in mesenteric segments
from CT, MtS and MtS-SYNB rats. Results are expressed as a % of previous contraction elicited by KCI
(in mN: CT: 13.03 ± 0.74; MtS: 11.55 ± 0.51; MtS-SYNB: 12.45 ± 0.72). Mean ± S.E.M. Statistical analysis:
Unpaired two-way ANOVA. * p < 0.05 CT vs. MtS; # p < 0.05 MtS vs. MtS-SYNB.
Next, we aimed to determine whether the observed alteration in NO release have a relevant
functional role. We applied EFS to induce a frequency-dependent contractile response in
endothelium-denuded mesenteric segments. An enhanced vasoconstriction response was observed in
MtS group, and the supplementation with Prodefen® Plus for 4 weeks diminished this vasoconstriction
response (Figure 5b). We next inhibited the NO synthesis with an unspecific NO synthase (NOS)
inhibitor L-NAME (0.1 mmol/L) and observed a potentiation in the vasoconstriction response in CT and
MtS-SYNB groups, while it exerted no effect in arteries from animals from MtS group (Figure 6a–d).
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Figure 6. Effect of preincubation with 0.1 mmol/L L-NAME (non-specific NOS inhibitor) on the
vasoconstrictor response elicited by EFS in mesenteric segments from CT (a), MtS (b) and MtS-SYNB (c)
rats. Results (mean ± S.E.M.) are expressed as a % of previous contraction elicited by KCl. Statistical
analysis: Paired two-way ANOVA. $ p < 0.05 segments without L-NAME vs. segments with L-NAME.
(d) Differences of area under the curve (dAUC) in the absence or presence of 0.1 mmol/L L-NAME.
Statistical analysis: One-way ANOVA followed by a Newman–Keuls post-hoc test. * p < 0.05 CT vs.
MtS; # p < 0.05 MtS vs. MtS-SYNB. (e) Expression of nNOS in mesenteric segments from CT, MtS and
MtS-SYNB rats. The blot is representative of eight separate segments from each group. The graph on
the right shows densitometric analyses of nNOS expression. Results (mean ± S.E.M.) are expressed as
the ratio of the signal obtained for nNOS and that obtained for β-actin.
3.3.3. Mechanisms Implicated in Neuronal Nitric Oxide Release
Alterations in nNOS expression and/or activity can be the responsible for the differences in NO
release observed. We found that the expression of nNOS was comparable among groups (Figure 6e).
PKA, PKC and PI3K/AKT signalling pathways play crucial role in the activation of nNOS.
To analyze the involvement of the PKA pathway, e preincubated the endothelium-denuded mesenteric
segments with a PKA inhibit r H89 (1 µmol/L) before EFS stimulation and m asurement of NO release.
W observed that H89 diminished EFS-induced NO release similarly in the CT gr up (60.69 ± 3.45% of
inhibition) and in MtS-SYNB group (50.19 ± 13.95% of i hibition) whil it produced a lower effect in
MtS group (20.48 ± 11.79% of inhibition). We next analysed the involvement of the PKC pathway by
using a PKC inhibitor Calfostin C (0.1 µmol/L), findig a similar inhibitio b in EFS-i duced NO releas
among t e experiment l groups (% f inhibition: CT: 76.41 ± 6.53; MtS: 57.33 ± 22.64; MtS-SYNB:
57.54 ± 12.71). Simil r results were found fte preincubation with LY394002 (10 µmol/L), a PI K
inhibitor (% of inhibition: CT: 83.96 ± 8.61; MtS: 60.51 ± 10.06; MtS-SYNB: 64.22 ± 8.46) (Figure 7a–c).
Nutrients 2020, 12, 117 11 of 18
Nutrients 2020, 12, x FOR PEER REVIEW 12 of 19 
 
 
Figure 7. Mesenteric segments from CT (a), MtS (b) and MtS-SYNB (c) rats were preincubated with a 
protein kinase A –PKA- inhibitor H89 (1 μmol/L), a protein kinase C –PKC- inhibitor Calfostin C (0.1 
μmol/L) or a phosphatidylinositol 3-kinase -PI3K- inhibitor LY294002 (10 μmol/L). NO release was 
induced by EFS. Data are expressed as arbitrary fluorescence units (A.F.U.)/mg tissue. Statistical 
analysis: One-way ANOVA followed by a Newman–Keuls post-hoc test. $ p < 0.05 conditions without 
inhibitor vs. conditions with respective inhibitor. 
This finding coincides with the PKA activity, which was significantly reduced in the MtS group 
as compared to the other two groups (Figure 8a). Similarly to previous findings, PKC activity and 
AKT expression and phosphorylation were comparable among groups (Figure 8b,c). 
 
Figure 8. (a) PKA activity, and (b) PKC activity in mesenteric arteries from CT, MtS and MtS-SYNB 
rats. Results are represented as optical density (OD) units/μg protein (mean ± S.E. M). Statistical 
analysis: One-way ANOVA followed by a Newman–Keuls post-hoc test. * p < 0.05 CT vs. MtS; # p < 
0.05 MtS vs. MtS-SYNB; + p < 0.05 CT vs. MtS-SYNB. (c) Western blot analysis for total AKT (AKT) 
and phosphorylated AKT at the T308 residue (P-AKT) in mesenteric arteries from CT, MtS and MtS-
SYNB rats. Each lane is representative of eight isolated arterial segments from different animals in 
each group. Lower graph shows densitometric analyses of the protein expression. Results (mean ± 
S.E.M) are expressed as protein expression relative to β-actin expression. 
3.3.4. Neuronal Nitric Oxide Bioavailability: Oxidative Stress 
Although oxidative stress can modulate NO function by diminishing its bioavailability, we 
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Figure 7. Mesenteric segments from CT (a), MtS (b) and MtS-SYNB (c) rats were preincubated with
a protein kinase A –PKA- inhibitor H89 (1 µmol/L), a protein kinase C –PKC- inhibitor Calfostin C
(0.1 µmol/L) or a phosphatidylinositol 3-kinase -PI3K- inhibitor LY294002 (10 µmol/L). NO release
was induced by EFS. Data are expressed as arbitrary fluorescence units (A.F.U.)/mg tissue. Statistical
analysis: One-way ANOVA followed by a Newman–Keuls post-hoc test. $ p < 0.05 conditions without
inhibitor vs. conditions with respective inhibitor.
This finding coincides with the PKA activity, which was significantly reduced in the MtS group as
compared to the other two groups (Figure 8a). Similarly to previous findings, PKC activity and AKT
expression and phosphorylation were comparable among groups (Figure 8b,c).
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Figure 8. (a) PKA activity, and (b) PKC activity in mesenteric arteries from CT, MtS and MtS-SYNB rats.
Results are represented as optical density (OD) units/µg protein (mean ± S.E.M). Statistical analysis:
One-way ANOVA followed by a Newman–Keuls post-hoc test. * p < 0.05 CT vs. MtS; # p < 0.05 MtS
vs. MtS-SYNB; + p < 0.05 CT vs. MtS-SYNB. (c) Western blot analysis for total AKT (AKT) and
phosphorylated AKT at the T308 residue (P-AKT) in mesenteric arteries from CT, MtS and MtS-SYNB
rats. Each lane is representative of eight isolated arterial seg ents from different animals in each group.
Lower graph shows densitometric analyses of the protein expression. Results (mean ± S.E.M) are
expressed as protein expression relative to β-actin expression.
3.3.4. Neuronal Nitric Oxide Bioavailability: Oxidative Stress
Although oxidative stress can modulate NO function by diminishing its bioavailability, we
observed that superoxid anion release was similar among groups (Table 3).
4. Discussion
Dietary factors, especially hypercaloric diets, are the main contributors to the aetiology of MtS [28].
Chronic consumption of HFD induces overweight along with metabolic and cardiovascular alterations,
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such as insulin resistance, dyslipidemia or hypertension, among others, being all of these symptoms of
the MtS [3,4]. Interestingly, studies in animal models demonstrated that HFD intake is related to gut
dysbiosis [29,30]. Gut dysbiosis can develop as early as 2 weeks on HFD, long before the development
of MtS-related symptoms [31].
Diets with a 45–60% of the energy derived from fats have been reported to promote a great
weight gain in animal models [32,33]. Here we have induced obesity by a diet containing 45% fat
and consistently with previous studies, we observed an increase in caloric intake together with body
weight gain coinciding with an increased weight of both visceral and epididymal adipose pads [9,10].
Furthermore, in our study, the supplementation of Prodefen® Plus for 4 weeks did not alter the body
weight nor the adiposity. Inconsistent results regarding the effect of a synbiotic supplementation
on body weight or adiposity index have been reported, showing either improvements [34,35] or no
alterations in the weight gain [36,37]. The discrepancies observed are probably caused by different
experimental procedures including the use of various probiotic strains. Clinical trials have also
reported inconsistent results in body weight changes after a probiotic or synbiotic supplementation [38],
moreover clinical trials also usually included changes in life or nutritional habits [39]. Therefore, more
studies are needed to evaluate the role of synbiotic supplementation on body weight change.
In our study, the level of TG was increased in rats fed with HFD as compared to standard diet,
while TC, HLD and LDL were not, similarly to previously published studies [9], but contrasting
with others, in which the dietary intervention was different from ours [24,40]. Liver steatosis is
linked to an increase in either TG and/or cholesterol levels, therefore in our study the liver steatosis
observed in rats fed with HFD was caused by an increase in TG levels, which is comparable to other
studies [40,41]. The supplementation of a synbiotic in our study decreased the TG levels to those
achieved with a standard diet together with the diminishment of hepatic lipid deposition as previously
described [41,42]. Even though basal glycemia was not altered in the MtS group, an insulin resistance
was established already at week eight and was improved by synbiotic administration. A number of
studies demonstrated that synbiotic supplementation leads to amelioration or a complete recovery
of glucose homeostasis [34,36,37], that can be linked to a normalization in adipokine levels [41,43].
Furthermore, the lowering of plasma TGs levels can also lead to the insulin resistance improvement [44].
The adipokines secreted by the adipose tissue alter the function of multiple vasoactive factors
participating in the increase in the peripheral vascular resistance and consequently in the development
of MtS-linked hypertension [5]. The HFD in rodents is associated with an increase or no modification of
blood pressure depending on the diet composition and duration [9,36,45]. Here we observed that HFD
induced an increase in systolic blood pressure, reaching levels that are considered as hypertension.
Synbiotic supplementation for 4 weeks diminished systolic blood pressure to values considered
as normotensive. The release of antihypertensive factors, such as propionate or butyrate, by the
probiotic strains, as well as the normalization of adipokine levels might explain the decrease in blood
pressure [41,43,46].
Previous works from our group have demonstrated that the mesenteric vasculature, especially
superior mesenteric artery, plays a pivotal role in the maintenance of peripheral resistance through the
release of vasodilators, such as NO [8]. Although alterations in blood pressure have been linked with
modifications in smooth muscle sensitivity to NO [6,47], we found no differences in the vasodilator
response to NO donor DEA-NO among our experimental groups, allowing us to rule out this possibility.
NO in the vascular tissue is predominantly released from the endothelium, and it has been
demonstrated that the decrease in endothelial NO release in obesity and MtS is the main factor for
endothelial dysfunction [3,48]. Aside from endothelium, NO is also released from perivascular nitrergic
innervation and this release is altered in situations in which vascular resistance is decreased [47,49].
Previously we have demonstrated that HFD intake diminishes NO release in superior mesenteric
artery [9,10]. Similarly to observed with endothelial NO [16,36], here we have shown that the
supplementation of MtS rats with synbiotics restore neuronal NO release, reaching levels comparable
in the CT group. NO released from nitrergic nerve terminals is able to decrease in a great extent the
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maximal arterial tone elicited by the sympathetic neurotransmitter noradrenaline [23,50]. In situations
where the vascular resistance is increased, we have previously observed either a potentiation in nitrergic
function, which aims to compensate the greater vascular resistance [23,51], or a blunted nitrergic role,
thereby participating in the enhancement of peripheral vascular resistance a consequently, in the
development of hypertension [47,49]. Here we observed an enhanced EFS-induced vasoconstrictor
response in MtS rats, as expected [9,10], and that the supplementation with Prodefen® Plus diminished
this vasoconstriction. When inhibiting NO synthesis with the unspecific NOS inhibitor L-NAME,
we observed a potentiation in the vasoconstriction in segments from CT and MtS-SYNB rats, while
it exerted no effect in arteries from MTS animals, as expected [9,10]. Consequently, we can confirm
that the supplementation with Prodefen® Plus restored the nitrergic function lost by MtS, therefore
improving the vascular resistance in this pathology.
Next, we wanted to find out whether the expression or the activity of nNOS, the enzyme
responsible for the synthesis of NO, is affected by MtS and synbiotic supplementation. We and
others have reported that the decrease in the different NOS isozymes, in different tissues is related to
obesity and MtS [9,10,52–54] and that probiotic or synbiotic supplementation led to an increase or no
modification in the expression of these isoforms [16,55,56]. In the present study we did not observe any
alteration in the nNOS expression among groups, a surprising finding given the fact that previously
we observed a diminishment of nNOS expression in superior mesenteric artery in rats on a HFD [9,10].
Therefore, we assumed that the increased fat content of the diet and prolonged administration activated
compensatory mechanisms, which might explain this difference. Consequently, we assumed that the
differential NO released among groups might be due to an alteration in nNOS activation rather than
nNOS expression, as we found in spontaneously hypertensive rats supplemented with the similar
formula Prodefen® [22].
Different kinases, such as PKA, PKC or PI3K/AKT pathways are essential for multiple physiological
responses. Alterations in these pathways have been reported in different MtS models, including
increases, decreases and no modifications in their activities [53,57–59]. Even though only few
inconsistent results were reported regarding the effect of probiotics and synbiotics on those
pathways [60–66], their role in the phosphorylation and subsequent activation of nNOS is well
demonstrated [27,51,67,68]. We found that the inhibition of either PKC or PI3K with calfostin C or
LY294002 respectively reduced EFS-induced NO release in a similar extent in the three experimental
groups. These results suggest that neither MTS nor supplementation with Prodefen® Plus altered the
participation of PKC or PI3K/AKT signalling pathways in our experimental conditions. This result
agrees with the fact that both the PKC activity, and the expression/activation of AKT were similar in the
three experimental groups. Concerning PKA, the preincubation with its specific inhibitor H89 blunted
EFS-induced NO release similarly in both CT and MtS-SYNB rats, while it exerted no effect in arteries
from MtS animals. This result correlates with the diminished PKA activity observed in segments
from MtS rats, which was restored to levels similar to those reached in CT after the administration
of Prodefen® Plus. Overall, the observed reduction of PKA activity in mesenteric arteries from MtS
rats presumably induced a decrease in nNOS activation and, consequently, a diminished NO release.
This inactivation of the PKA-nNOS-NO pathway was recovered by supplementation of Prodefen® Plus
for 4 weeks.
NO function can be also influenced by oxidative stress. The amount and the kind of dietary
fatty acids can regulate complex intracellular signalling systems, thereby modulating cellular function
and promoting a pro-oxidative microenvironment, which reduces NO bioavailability [5,62]. At the
vascular level, an increase in superoxide anion metabolizes NO, forming peroxynitrite [27]. Hence,
superoxide anion reduces the availability of NO and participates in the development of the vascular
disturbances observed in MtS. Since different probiotic strains have been reported to potentiate several
antioxidant routes [16,69], the alterations in NO observed in our experimental conditions might be
due to modifications in vascular oxidative stress status. However, we found no differences among the
different groups when measuring superoxide anion formation, allowing us to rule out a possible role
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of oxidative stress in the nitrergic modifications observed in the present study. We should point out
that, although both smooth muscle and adventitial layers can be a source of superoxide anions, the
endothelial layer, removed in the present study, also has a relevant role in producing these reactive
oxygen species [70–72].
5. Conclusions
Overall, our data describe a beneficial effect of Prodefen® Plus regarding the different metabolic
associated to MtS. Additionally, Prodefen® Plus improves different mechanisms implicated in the
regulation of vascular tone, therefore ameliorating the hypertension associated to this condition.
In conclusion, the commercially available formula Prodefen® Plus could be considered an interesting
non-pharmacological approach in MtS.
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